Technophage is excited to kick off the new year by sharing our latest publication in Med by Cell Press. Our Phase I/IIa study results for TP-102, an innovative bacteriophage cocktail targeting infected diabetic foot ulcers, demonstrated promising outcomes and are depicted in the paper entitled “Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers“.
The randomized trial confirmed that TP-102 is safe and well-tolerated, with no adverse events reported. It reduced bacterial load in infected ulcers and showed encouraging signs of wound healing in treated patients. While further research is needed – Phase IIb is already underway – this work underscores the potential of bacteriophage therapy as a groundbreaking alternative for managing diabetic foot infections.
The paper was first released online on December 30 and will be included in the January 2025 edition of Med. Technophage eagerly anticipates concluding the ongoing clinical research on TP-102 to advance toward publishing the results of Phase IIb.